Nexalis Therapeutics Limited has released a press release.
Removal of draft wording in the directors report HY accounts
Earlier from Nexalis Therapeutics
- Jun26 Appendix 4C Cash Flow Report
- Update on Funding Facility and Clinical Program
- Binding Letter of Intent to replace existing $53m facility
- Suspension from Quotation